← TrialMatch
HomeTrials

Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tub

This study aims to compare the effects of using prophylactic abdominal drainage tubes during Enhanced Recovery After Surgery (ERAS) in patients undergoing Laparoscopic Distal Gastrectomy (LDG) for gastric cancer through a multicenter non-inferiority randomized trial. The study is divided into two groups: 1. ERAS-tubele

Condition(s)Gastric Adenocarcinoma, Laparoscopic Gastrectomy, Complications
StatusRecruiting
PhasePhase 3
Study typeInterventional
SummaryThis study aims to compare the effects of using prophylactic abdominal drainage tubes during Enhanced Recovery After Surgery (ERAS) in patients undergoing Laparoscopic Distal Gastrectomy (LDG) for gastric cancer through a multicenter non-inferiority randomized trial. The study is divided into two groups: 1. ERAS-tubeless group: The ERAS protocol without nasogastric decompression, nasojejunal feeding or prophylactic abdominal drainage tubes. 2. ERAS-tube group: the ERAS protocol with prophylactic abdominal drainage tubes, along with no nasogastric decompression or nasojejunal feeding tubes. Patients will be randomly assigned to the two groups in a 1:1 ratio, with the primary analysis based on the modified intention-to-treat population (mITT) and secondary analysis on the per-protocol (PP) p
Who can participateInclusion Criteria: 1. Patients' age from 18 to 80 years old; 2. Histopathologically confirmed gastric adenocarcinoma; 3. Clinical tumor stage of cT1-4N0-3M0; 4. Laparoscopic distal gastrectomy approach; 5. ECOG score of 0-1; 6. Written informed consent Exclusion Criteria: 1. Patients with severe concurrent illness or comorbid diseases; 2. Patients with severe pyloric obstruction, recurrent or remnant gastric cancer; 3. Patients with perforation, or undergoing emergency surgery; 4\. Patients with a history of radiotherapy; 5. Patients undergoing complex abdominal surgeries other than laparoscopic cholecystectomy or appendectomy; 6. Patients with peritoneal, hepatic or ovarian metastasis, or simultaneous tumors in other parts of the body preoperatively and intraoperatively; 7. Patients with
Ages18 Years to 80 Years
SexAll
Lead sponsorZuoyi Jiao
LocationsBeijing, Beijing Municipality, China; Fuzhou, Fujian, China; Lanzhou, Gansu, China; Lanzhou, Gansu, China; Zhejiang, Hangzhou, China; Xi'an, Xi'an City, China
Start date2025-06-16
NCT IDNCT07029269
Official listinghttps://clinicaltrials.gov/study/NCT07029269

🔍 Search all trials →